Skip to main content
. 2022 Jun 20;127(6):1142–1152. doi: 10.1038/s41416-022-01886-4

Fig. 6. M-CSF plasma levels determine melanoma OS and DFS in metastatic melanoma patients.

Fig. 6

a Timeline of plasma collection and patient treatment. b Clinical parameters from 35 patients with BRAFV600E advanced-stage melanoma. MAP kinase-targeted therapy: BRAFi (Vemurafenib, Dabrafenib or LGX818) in monotherapy or in combination with MEKi (Dabrafenib/Trametinib, LGX818/MEK162, Vemurafenib/Cobimetinib). Response to the treatment: complete response (CR), partial responders (PR), and non-responders (stable disease (SD) and progressive disease (PD)). c Kaplan–Meier of melanoma overall survival (mOS) curve of metastatic melanoma patients (n = 17) with <5 ng/mL of M-CSF vs. >5 ng/mL. d Contingency of alive/dead patients depending on their M-CSF levels and e analysis of M-CSF plasma levels depending on the status of the patients (alive/dead). f Kaplan–Meier of melanoma disease-free survival (%DFS) of metastatic melanoma patients with <5 ng/mL vs. > 5 ng/mL of M-CSF plasma levels. g M-CSF levels depending on time to relapse after treatment (<12 vs. >12 months). Fisher exact tests were used to examine clinical variables and the ANOVA test for the statistical analysis of M-CSF plasma levels. Melanoma overall survival (mOS) and disease-free survival (DFS) curves were calculated using the Kaplan–Meier method with a log-rank test. p-values are indicated by asterisks *p < 0.05; **p < 0.01; ***p < 0.001.